

YEAR IN REVIEW 2021



Purpose: This report provides cumulative and updated statistics about the emergence and landscape of novel psychoactive substances (NPS) in the United States based on data developed by NPS Discovery at the CFSRE — a premier open-access drug early warning system utilizing an evidence-based approach to disseminate information for real-time public health and safety actions.

Since 2018, NPS Discovery has reported **116** newly discovered NPS in the United States (Figure 1). **NPS opioids** remain the largest subclass (Figure 2). In 2021, NPS Discovery reported the discovery of **27** NPS for the first time.




Figure 1: Newly discovered NPS reported for the first time since 2018.




Figure 2: Breakdown by subclass of newly discovered NPS, 2018-2021.

Since 2018, NPS Discovery has identified **197** NPS in forensic samples (Figure 3). **NPS opioids, stimulants, and cannabinoids** represent the largest subclasses observed. In 2021, **97** total NPS were detected (Figure 4).




Figure 3: Breakdown by subclass of individual NPS detected, 2018-2021.




Figure 4: Individual NPS detected each year, cumulative since 2018.

In 2021, NPS Discovery observed more than **2700** total NPS detections within examined sample populations (Table 5), a portion of more than **8100** total NPS detections since our program launched in 2018 (Figure 6).




Figure 5: Total number of NPS detections among all samples analyzed since 2018.




Figure 6: Cumulative number of NPS detections since 2018.

Acknowledgements: This report was prepared at the Center for Forensic Science Research and Education (CFSRE) at the Fredric Rieders Family Foundation by Alex Krotulski, Donna Papsun, Sara Walton, Melissa Fogarty, and Barry Logan. The authors acknowledge scientists and staff at the CFSRE for their involvements and contributions.

Recommended Citation: Krotulski, AJ; Papsun, DM; Walton, SE; Fogarty, MF; Logan, BK (2021). NPS Discovery: Year in Review 2021, Center for Forensic Science Research and Education, United States.

Funding: NPS Discovery at the CFSRE is funded in part by the National Institute of Justice, Office of Justice Programs, U.S. Department of Justice (Award Number 2020-DQ-BX-0007, "Real-Time Sample-Mining and Data-Mining Approaches for the Discovery of Novel Psychoactive Substances (NPS)"). The opinions, findings, conclusions, and/or recommendations expressed in this publication are those of the author(s) and do not necessarily reflect those of the Department of Justice.

